Rescriptor and Partial lung collapse - a phase IV clinical study of FDA data

Summary:

We study 17,513 people who take Rescriptor (delavirdine mesylate) or have Partial lung collapse. No report of Partial lung collapse is found in people who take Rescriptor.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

What is Rescriptor?

Rescriptor has active ingredients of delavirdine mesylate. eHealthMe is studying from 426 Rescriptor users. Check the latest studies of Rescriptor.

What is Partial Lung Collapse?

Partial lung collapse is found to be associated with 2,018 drugs and 1,649 conditions by eHealthMe. Check the latest studies of Partial lung collapse.

On Jun, 24, 2026

No report is found.

Do you take Rescriptor and have Partial lung collapse?

- Check whether Partial lung collapse is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rescriptor:

Rescriptor (426 reports)

Browse all side effects of Rescriptor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Partial lung collapse:

Partial lung collapse

Browse all the conditions that are associated with Partial lung collapse:

Partial lung collapse

How the study uses the data?

The study uses data from the FDA. It is based on delavirdine mesylate (the active ingredients of Rescriptor) and Rescriptor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.